# Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

> **NCT05842525** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** intensive treatment
- **DRUG:** Maintenance treatment

## Key facts

- **NCT ID:** NCT05842525
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-12-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05842525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05842525, "Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05842525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*